Randomized trial of two after-dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients

  • Giovanni Maria Rossi
  • Mattia Corradini
  • Valentina Blanco
  • Silvia Mattei
  • Enrico Fiaccadori
  • Augusto Vaglio
  • Lucio ManentiEmail author
CE - Research Letter to the Editor

Uremic pruritus (UP) has an overall reported incidence of ~ 46% in patients on hemodialysis, and is a relevant issue in the management of CKD [1, 2]. Gabapentin seems to be the best available treatment option, but since it is mainly eliminated by the kidneys, neurotoxicity is a concern, and sleepiness is the most frequently reported adverse reaction in clinical trials [2].

In this randomized, double-blind, placebo-controlled trial of gabapentin in hemodialysis patients with UP, we sought to determine the efficacy of two fixed-dose, after-dialysis drug regimens versus placebo.

Patients on thrice-weekly hemodialysis who met the following criteria were included: (1) age above 18 years; (2) history of itch for more than 6 weeks as per the definition of chronic itch by the International Forum for the Study of Itch [3]; (3) female subjects had to be willing to use adequate contraception; (4) a negative serum pregnancy test at initial screening of female subjects with childbearing potential.




This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Statement of human and animal rights

All procedures were approved by the Azienda Ospedaliera S. Maria Nuova of Reggio Emilia Ethical Committee, and were compliant with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All participants provided informed consent prior to their participation.


  1. 1.
    Schena FP (2011) Management of patients with chronic kidney disease. Intern Emerg Med 6(Suppl 1):77–83CrossRefGoogle Scholar
  2. 2.
    Simonsen E, Komenda P, Lerner B et al (2017) Treatment of uremic pruritus: a systematic review. Am J Kidney Dis 70(5):638–655CrossRefGoogle Scholar
  3. 3.
    Stander S, Weisshaar E, Mettang T et al (2007) Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 87(4):291–294CrossRefGoogle Scholar
  4. 4.
    Casino FG, Lopez T (1996) The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Renal Assoc 11(8):1574–1581Google Scholar
  5. 5.
    Friedman LM, Furberg C, DeMets DL (1998) Fundamentals of clinical trials, 3rd edn. Springer, New YorkCrossRefGoogle Scholar
  6. 6.
    Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H (2004) Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Renal Assoc 19(12):3137–3139Google Scholar
  7. 7.
    Manenti L, Vaglio A, Costantino E et al (2005) Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 18(1):86–91Google Scholar
  8. 8.
    Naini AE, Harandi AA, Khanbabapour S, Shahidi S, Seirafiyan S, Mohseni M (2007) Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi J Kidney Dis Transpl 18(3):378–381Google Scholar
  9. 9.
    Pongcharoen P, Fleischer AB Jr (2016) An evidence-based review of systemic treatments for itch. Eur J Pain 20(1):24–31CrossRefGoogle Scholar
  10. 10.
    Collins SL, Moore RA, McQuay HJ (1997) The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 72(1–2):95–97CrossRefGoogle Scholar
  11. 11.
    Pauli-Magnus C, Mikus G, Alscher DM et al (2000) Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 11(3):514–519Google Scholar
  12. 12.
    (U.S.) NCI (2009) Common terminology criteria for adverse events (CTCAE). Rev. ed. U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, BethesdaGoogle Scholar
  13. 13.
    Nofal E, Farag F, Nofal A, Eldesouky F, Alkot R, Abdelkhalik Z (2016) Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. J Dermatol Treat 27(6):515–519CrossRefGoogle Scholar
  14. 14.
    Solak Y, Biyik Z, Atalay H et al (2012) Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) 17(8):710–717CrossRefGoogle Scholar
  15. 15.
    Manenti L, Tansinda P, Vaglio A (2009) Uraemic pruritus: clinical characteristics, pathophysiology and treatment. Drugs 69(3):251–263CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  • Giovanni Maria Rossi
    • 1
  • Mattia Corradini
    • 2
  • Valentina Blanco
    • 3
  • Silvia Mattei
    • 2
  • Enrico Fiaccadori
    • 1
  • Augusto Vaglio
    • 4
    • 5
  • Lucio Manenti
    • 1
    Email author
  1. 1.U.O. Nefrologia, Dipartimento di Medicina Generale e SpecialisticaAzienda Ospedaliero-Universitaria di ParmaParmaItaly
  2. 2.Nephrology and Dialysis UnitAzienda USL-IRCCS di Reggio EmiliaReggio EmiliaItaly
  3. 3.Renal Unit, Nephrology and Dialysis DepartmentSant’Andrea HospitalLa SpeziaItaly
  4. 4.Department of Biomedical Clinical and Experimental Sciences “Mario Serio”University of FirenzeFlorenceItaly
  5. 5.Meyer Children’s HospitalFlorenceItaly

Personalised recommendations